(Q41462524)

1 October 2017

Retrospective review of the effects of rhDNase in children with cystic fibrosis (English)

1 reference

1 October 2017

0 references

Davies J

1

1 reference

1 October 2017

Trindade MT

2

1 reference

1 October 2017

Wallis C

3

1 reference

1 October 2017

Rosenthal M

4

1 reference

1 October 2017

Crawford O

5

1 reference

1 October 2017

Bush A

6

1 reference

1 October 2017

1 April 1997

1 reference

1 October 2017

Pediatric Pulmonology

1 reference

1 October 2017

23

1 reference

1 October 2017

4

1 reference

1 October 2017

243-248

1 reference

Cystic fibrosis in adolescents and adults

1 October 2017

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Pus, deoxyribonucleic acid, and sputum viscosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

PURIFICATION AND PROPERTIES OF DESOXYRIBONUCLEASE ISOLATED FROM BEEF PANCREAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Dornase alfa for cystic fibrosis. Patients should not be denied a safe, effective treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Liquefaction of viscous purulent exudates by deoxyribonuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

Dornase-alfa for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-0496%28199704%2923%3A4%3C243%3A%3AAID-PPUL1%3E3.0.CO%3B2-N

10.1002/(SICI)1099-0496(199704)23:4<243::AID-PPUL1>3.0.CO;2-N

21 January 2018

Identifiers

DOI

1 reference

1 October 2017

1 reference